Skip to content

Sample Page

Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis

Written by

in

For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study

Continue Reading

News Source: medicalxpress.com

←Updated: Israeli Soldiers Shoot Three Palestinians Near Ramallah |

Mbappe and Dembele net as France beat Morocco to reach World Cup semifinal | World Cup 2026 News→

Comments

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

More posts

Cyclosporiasis Is Spreading Across The United States— Here’s What To Know

July 9, 2026
Lower dementia risk seen with sodium-glucose cotransporter 2 in seniors 65+ with mood, psychotic disorders

July 9, 2026
Mbappe and Dembele net as France beat Morocco to reach World Cup semifinal | World Cup 2026 News

July 9, 2026
Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis

July 9, 2026

Palestine News

Blog
About
FAQs
Authors

Events
Shop
Patterns
Themes

Twenty Twenty-Five

Designed with WordPress